
Endpoints at #JPM25 - January 13-14, 2025 - San Francisco
In the biopharma world, the new year doesn’t start on January 1 — it starts when the industry descends on San Francisco for JPM. Dealmakers, investors, and corporate leaders will gather to chart the course for 2025 and take stock of the landscape, both financial and political.
Endpoints News – Biotech and pharma business news, with a focus …
Biotech and pharma business news, with a focus on the science, people and money that drive the industry.
Pharma is losing the AI talent war against startups: Analysis
Jan 11, 2025 · Last month, NeurIPS, the biggest AI research conference, turned Vancouver’s convention center into a battleground for wooing AI talent. The recruiting trenches of the expo floor featured ...
Charles River offers damp 2025 outlook for investors
Jan 14, 2025 · Charles River Laboratories is predicting 2025 to be as tough as last year for CDMOs as pharma customers continue to cut costs with manufacturers. …
FAQ: Endpoints at #JPM25 - events.endpts.com
For in the in-person event, a badge is required to get in — registration will open both mornings right outside our event space.. The venue is located in San Francisco Marriott Marquis, 780 Mission Street, San Francisco, CA 94103; The ballroom name is …
Agenda: Endpoints at #JPM25 - events.endpts.com
Jan 13, 2025 · How a new Washington affects biopharma: In conversation with Scott Gottlieb . Investor, policy expert and former FDA Commissioner Scott Gottlieb will share his insights on how the Trump administration’s new priorities will affect the biopharma industry, in what could be a turbulent time of policy and political changes.
The Endpoints 100 survey: What are industry execs saying about …
Twice a year, I run the Endpoints 100 survey, checking in with 100+ industry execs — mostly CEOs — about the state of biotech today. There have been good times, bad times and the last 18 months, which have left more than a few bruises.
The Endpoints 100 survey: What are biopharma execs saying …
Dec 11, 2024 · We’ve asked our advisory group in the E100 about how things are shaping up at the FDA and HHS under the new Trump administration and what impact prospective changes could have on the drug development industry. Also, they have insights on the tense China-US relations and drug development, AI and our continuing focus on financing at …
Health tech funding in 2025 kicks off with megarounds
Jan 14, 2025 · Health tech sees strong start to 2025 with five $100M+ funding rounds, including Evergreen Nephrology, Qventus, LetsGetChecked, Innovaccer, and Hippocratic AI.
Endpoints at JPM 2025: China, Trump 2.0, markets and more
Jan 10, 2025 · JPM agenda focuses on Trump 2.0 transition, market recovery & US-China dynamics, featuring talks with Sanofi's Ashrafian, ARCH's Nelsen, Scott Gottlieb & other leaders.